Hemin

File:Hemin.svg

Hemin.svg

Hemin is a porphyrin derivative, specifically a heme-containing compound. It is used in the treatment of certain medical conditions, particularly those related to heme synthesis disorders. Hemin is also known by its trade name, Panhematin.

Medical Uses

Hemin is primarily used in the management of acute porphyria attacks. Porphyria refers to a group of disorders caused by abnormalities in the chemical steps leading to the production of heme. Hemin works by providing a source of heme, which helps to reduce the overproduction of porphyrin precursors that cause the symptoms of acute porphyria.

Mechanism of Action

Hemin acts by inhibiting the enzyme aminolevulinic acid synthase (ALAS1), which is the first enzyme in the heme synthesis pathway. By downregulating this enzyme, hemin reduces the accumulation of toxic intermediates that are responsible for the symptoms of acute porphyria.

Administration

Hemin is administered intravenously. The dosage and duration of treatment depend on the severity of the porphyria attack and the patient's response to the medication. It is typically given in a hospital setting under the supervision of a healthcare professional.

Side Effects

Common side effects of hemin include phlebitis at the injection site, headache, and fever. More serious side effects can include anaphylaxis and renal impairment. Patients receiving hemin should be monitored for these potential adverse effects.

History

Hemin was first approved for medical use in the United States in 1983. It has since become a critical treatment option for managing acute porphyria attacks, significantly improving the quality of life for patients with this condition.

See Also

• Porphyria
• Heme
• Aminolevulinic acid synthase
• Intravenous therapy